2022 Hemostasis Gordon Research Conference and Seminar

项目摘要/摘要 我们请求为止血戈登研究研讨会(GRS)和戈登研究提供部分支持 会议(GRC)，2022年7月31日至8月5日，在密歇根州沃特维尔山谷举行。2022年止血GRC是第35届 这一系列会议被广泛认为是止血和 血栓形成研究。这一重要主题与NIH在两个关键领域的战略目标密切一致：1) 了解止血机制，减少止血和血栓疾病的发病率和死亡率； 包括中风、心肌梗死、静脉血栓栓塞症和外伤性凝血障碍，以及2) 增加生物医学研究队伍。此外，最近的研究表明，传统上 认为止血系统在凝血之外具有更广泛的重要性，在炎症中发挥作用，天生 免疫力、肥胖症、糖尿病和癌症。止血GRS/GRC将感兴趣的研究人员聚集在一起 凝血蛋白和血小板的生物学、生化和遗传学；治疗出血的内科医生 和血栓性疾病，来自制药公司的科学家开发止血的新疗法 疾病，以及致力于止血和止血研究事业的实习生和初级教员 血栓形成。这些研究人员一起讨论最先进的研究并探索新的研究 止血和血栓形成的机会及其在医学相关领域的应用。事实上，许多关键 这一领域的进展已经在以往的止血GRC上首次亮相。国际知名科学家参与 并通过密切互动和互动交流，激励受训人员和初级调查人员。免费 所有与会者之间的思想交流和未发表的研究成果是我们GRS/GRC的关键。此外，一个优先事项是 妇女、任职人数不足的人口、肢体残疾人士和青年的参与 调查人员，包括研究生和博士后实习生，以及初级教职员工。2022年止血GRS是 专门致力于通过学员发展来加强生物医学研究队伍的目标 活动和指导GRS由受训人员组织和运营。它非常成功，并增强了 GRC的实习生简介。2022年止血GRC计划包括来自两个国家的主题演讲 非常成功的科学家，罗伯特·蒙哥马利博士和爱德华·普洛博士，39次演讲和海报。8、口试和 4个主题集中在凝血：信号和结构；凝血和血小板 炎症；维持止血平衡；血栓和深静脉血栓结构；教训 以血液为食的生物体的分子止血；慢性疾病中的凝血和血小板； 出血和凝血控制系统。重要的是，我们将继续举办热门话题会议 8名受训者介绍他们的工作的抽象衍生演讲。

Project Summary/Abstract We request partial support for the Hemostasis Gordon Research Seminar (GRS) and Gordon Research Conference (GRC), July 31-August 5, 2022, in Waterville Valley, NH. The 2022 Hemostasis GRC is the 35th meeting in this series which is widely considered as the premier scientific meeting for hemostasis and thrombosis research. This important topic closely aligns with NIH strategic goals in two critical areas: 1) to understand mechanisms and reduce morbidity and mortality from hemostatic and thrombotic diseases, including stroke, myocardial infarction, venous thromboembolism, and trauma-induced coagulopathy and 2) to increase the biomedical research workforce. Furthermore, recent research has shown that the traditionally considered hemostatic system has wider importance beyond clotting, playing roles in inflammation, innate immunity, obesity, diabetes, and cancer. The Hemostasis GRS/GRC brings together researchers interested in the biology, biochemistry, and genetics of blood clotting proteins and platelets; physicians treating bleeding and thrombotic diseases, scientists from pharmaceutical companies developing new therapies for hemostatic disorders, and trainees and junior faculty who are committed to research careers in hemostasis and thrombosis. Together, these investigators discuss state-of-the-art research and explore new research opportunities in hemostasis and thrombosis and their applications in medically related fields. Indeed, many key advances in this field have debuted at previous Hemostasis GRCs. Internationally renowned scientists engage and motivate trainees and junior investigators through close interactions and interactive exchanges. Free exchange of ideas and unpublished research, among all attendees, is a key to our GRS/GRC. Also, a priority is participation by women, underrepresented populations, individuals with physical disabilities, and young investigators, including graduate and postdoctoral trainees, and junior faculty. The 2022 Hemostasis GRS is specifically dedicated to the goal of enhancing the biomedical research workforce through trainee development activities and mentoring The GRS is organized and run by trainees. It is highly successful and enhances the profile of trainees at the GRC. The 2022 Hemostasis GRC program includes keynote addresses from two highly successful scientists, Drs. Robert Montgomery and Edward Plow, 39 talks, and posters. The 8 oral and 4 poster sessions focus on topics including Coagulation: Signaling and Structure; Coagulation and Platelets in Inflammation; Maintaining Hemostatic Balance; Clot and Deep Vein Thrombosis Structure; Lessons of Molecular Hemostasis from Organisms that Feed on Blood; Coagulation and Platelets in Chronic Diseases; and Bleeding and Clotting Control. Importantly, we will continue the practice of holding a “Hot Topics” session of abstract-derived talks during which 8 trainees present their work.